Kailera Therapeutics (NASDAQ:KLRA) Stock Breaks Above 50 Day Moving Average – Here’s What Happened

Kailera Therapeutics, Inc. (NASDAQ:KLRA)’s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $12.78 and traded as high as $13.26. Kailera Therapeutics shares last traded at $12.97, with a volume of 733,039 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Kailera Therapeutics Stock Performance

The stock’s 50 day moving average is $12.78. The firm has a market cap of $1.68 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.81. Sell-side analysts predict that Kailera Therapeutics, Inc. will post -3.89 EPS for the current fiscal year.

Institutional Trading of Kailera Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Aberdeen Group plc raised its position in shares of Kailera Therapeutics by 209.0% during the 3rd quarter. Aberdeen Group plc now owns 432,661 shares of the company’s stock valued at $4,941,000 after acquiring an additional 292,661 shares in the last quarter. Alps Advisors Inc. lifted its stake in Kailera Therapeutics by 31.1% during the third quarter. Alps Advisors Inc. now owns 171,739 shares of the company’s stock worth $1,961,000 after purchasing an additional 40,739 shares during the last quarter. Commonwealth Equity Services LLC bought a new position in Kailera Therapeutics during the third quarter worth $134,000. Profund Advisors LLC acquired a new position in Kailera Therapeutics in the third quarter worth $216,000. Finally, Mirador Capital Partners LP acquired a new position in Kailera Therapeutics in the third quarter worth $666,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.